Cargando…

Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor

Atherothrombosis, thrombus formation as a result of atherosclerotic plaque rupture, is a major modern health problem, often underlying coronary artery disease, stroke, and peripheral arterial disease. After the treatment of an acute thrombotic episode, long-term therapy is warranted as a secondary p...

Descripción completa

Detalles Bibliográficos
Autores principales: Marczewski, Margaret M, Postula, Marek, Kosior, Dariusz
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882894/
https://www.ncbi.nlm.nih.gov/pubmed/20539844
_version_ 1782182213086871552
author Marczewski, Margaret M
Postula, Marek
Kosior, Dariusz
author_facet Marczewski, Margaret M
Postula, Marek
Kosior, Dariusz
author_sort Marczewski, Margaret M
collection PubMed
description Atherothrombosis, thrombus formation as a result of atherosclerotic plaque rupture, is a major modern health problem, often underlying coronary artery disease, stroke, and peripheral arterial disease. After the treatment of an acute thrombotic episode, long-term therapy is warranted as a secondary prophylaxis of such events and their complications. Because of the importance of platelets’ involvement in the initiation and propagation of thrombosis, antiplatelet drugs have come to the forefront of atherothrombotic disease treatment. Dual antiplatelet therapy of aspirin plus clopidogrel – the current standard – has its benefits, but it also has its limitations with regard to its pharmacologic properties and adverse effects. For these reasons, within the last decade or so, the investigation of novel antiplatelet agents has prospered. Here, we review the main pathways through which platelets participate in acute thrombosis and the interruption of these pathways by using novel antiplatelet agents, including P2Y(12) receptor antagonists (the recently approved prasugrel, the probable next-in-line ticagrelor, and others). The need for a more individualized patient therapy is evident; although most of the aforementioned pharmaceuticals have the potential to contribute to this, their clinical utility remains to be seen.
format Text
id pubmed-2882894
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-28828942010-06-10 Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor Marczewski, Margaret M Postula, Marek Kosior, Dariusz Vasc Health Risk Manag Review Atherothrombosis, thrombus formation as a result of atherosclerotic plaque rupture, is a major modern health problem, often underlying coronary artery disease, stroke, and peripheral arterial disease. After the treatment of an acute thrombotic episode, long-term therapy is warranted as a secondary prophylaxis of such events and their complications. Because of the importance of platelets’ involvement in the initiation and propagation of thrombosis, antiplatelet drugs have come to the forefront of atherothrombotic disease treatment. Dual antiplatelet therapy of aspirin plus clopidogrel – the current standard – has its benefits, but it also has its limitations with regard to its pharmacologic properties and adverse effects. For these reasons, within the last decade or so, the investigation of novel antiplatelet agents has prospered. Here, we review the main pathways through which platelets participate in acute thrombosis and the interruption of these pathways by using novel antiplatelet agents, including P2Y(12) receptor antagonists (the recently approved prasugrel, the probable next-in-line ticagrelor, and others). The need for a more individualized patient therapy is evident; although most of the aforementioned pharmaceuticals have the potential to contribute to this, their clinical utility remains to be seen. Dove Medical Press 2010 2010-06-01 /pmc/articles/PMC2882894/ /pubmed/20539844 Text en © 2010 Marczewski et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Marczewski, Margaret M
Postula, Marek
Kosior, Dariusz
Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
title Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
title_full Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
title_fullStr Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
title_full_unstemmed Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
title_short Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
title_sort novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882894/
https://www.ncbi.nlm.nih.gov/pubmed/20539844
work_keys_str_mv AT marczewskimargaretm novelantiplateletagentsinthepreventionofcardiovascularcomplicationsfocusonticagrelor
AT postulamarek novelantiplateletagentsinthepreventionofcardiovascularcomplicationsfocusonticagrelor
AT kosiordariusz novelantiplateletagentsinthepreventionofcardiovascularcomplicationsfocusonticagrelor